Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: A meta-analysis

Xianhui Qin, Yong Huo, Craig B. Langman, Fanfan Hou, Yundai Chen, Debora Matossian, Xiping Xu, Xiaobin Wang

Research output: Contribution to journalArticle

Abstract

Background and objectives: The efficacy of folic acid therapy to lower homocysteine (Hcy) levels in an effort to reduce cardiovascular disease (CVD) risk in patients with ESRD or advanced chronic kidney disease (ACKD; creatinine clearance, 24 months (RR, 0.84; 95% CI, 0.72 to 0.98; P = 0.02), a decrease in Hcy level >20% (RR, 0.83; 95% CI, 0.73 to 0.95; P = 0.007), and no or partial folic acid fortification (RR, 0.80; 95% CI, 0.65 to 0.99; P = 0.04). The beneficial effect also was seen when Hcy levels decreased >20%, even in the presence of folic acid fortification (RR, 0.85; 95% CI, 0.73 to 0.99; P = 0.04). In the corresponding comparison groups, the estimated RRs were attenuated and insignificant. Conclusions: Folic acid therapy can reduce CVD risk in patients with ESRD/ACKD by 15%. A greater beneficial effect was observed among those trials with no or partial folic acid fortification or a decrease in Hcy level >20% regardless of folic acid fortification.

Original languageEnglish (US)
Pages (from-to)482-488
Number of pages7
JournalClinical Journal of the American Society of Nephrology
Volume6
Issue number3
DOIs
StatePublished - Mar 1 2011
Externally publishedYes

Fingerprint

Chronic Renal Insufficiency
Folic Acid
Chronic Kidney Failure
Meta-Analysis
Cardiovascular Diseases
Homocysteine
Therapeutics
Creatinine

ASJC Scopus subject areas

  • Nephrology
  • Transplantation
  • Epidemiology
  • Critical Care and Intensive Care Medicine

Cite this

Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease : A meta-analysis. / Qin, Xianhui; Huo, Yong; Langman, Craig B.; Hou, Fanfan; Chen, Yundai; Matossian, Debora; Xu, Xiping; Wang, Xiaobin.

In: Clinical Journal of the American Society of Nephrology, Vol. 6, No. 3, 01.03.2011, p. 482-488.

Research output: Contribution to journalArticle

Qin, Xianhui ; Huo, Yong ; Langman, Craig B. ; Hou, Fanfan ; Chen, Yundai ; Matossian, Debora ; Xu, Xiping ; Wang, Xiaobin. / Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease : A meta-analysis. In: Clinical Journal of the American Society of Nephrology. 2011 ; Vol. 6, No. 3. pp. 482-488.
@article{cd77cde0fcc645e49b93cf1f0946e4ad,
title = "Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: A meta-analysis",
abstract = "Background and objectives: The efficacy of folic acid therapy to lower homocysteine (Hcy) levels in an effort to reduce cardiovascular disease (CVD) risk in patients with ESRD or advanced chronic kidney disease (ACKD; creatinine clearance, 24 months (RR, 0.84; 95{\%} CI, 0.72 to 0.98; P = 0.02), a decrease in Hcy level >20{\%} (RR, 0.83; 95{\%} CI, 0.73 to 0.95; P = 0.007), and no or partial folic acid fortification (RR, 0.80; 95{\%} CI, 0.65 to 0.99; P = 0.04). The beneficial effect also was seen when Hcy levels decreased >20{\%}, even in the presence of folic acid fortification (RR, 0.85; 95{\%} CI, 0.73 to 0.99; P = 0.04). In the corresponding comparison groups, the estimated RRs were attenuated and insignificant. Conclusions: Folic acid therapy can reduce CVD risk in patients with ESRD/ACKD by 15{\%}. A greater beneficial effect was observed among those trials with no or partial folic acid fortification or a decrease in Hcy level >20{\%} regardless of folic acid fortification.",
author = "Xianhui Qin and Yong Huo and Langman, {Craig B.} and Fanfan Hou and Yundai Chen and Debora Matossian and Xiping Xu and Xiaobin Wang",
year = "2011",
month = "3",
day = "1",
doi = "10.2215/CJN.05310610",
language = "English (US)",
volume = "6",
pages = "482--488",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "3",

}

TY - JOUR

T1 - Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease

T2 - A meta-analysis

AU - Qin, Xianhui

AU - Huo, Yong

AU - Langman, Craig B.

AU - Hou, Fanfan

AU - Chen, Yundai

AU - Matossian, Debora

AU - Xu, Xiping

AU - Wang, Xiaobin

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Background and objectives: The efficacy of folic acid therapy to lower homocysteine (Hcy) levels in an effort to reduce cardiovascular disease (CVD) risk in patients with ESRD or advanced chronic kidney disease (ACKD; creatinine clearance, 24 months (RR, 0.84; 95% CI, 0.72 to 0.98; P = 0.02), a decrease in Hcy level >20% (RR, 0.83; 95% CI, 0.73 to 0.95; P = 0.007), and no or partial folic acid fortification (RR, 0.80; 95% CI, 0.65 to 0.99; P = 0.04). The beneficial effect also was seen when Hcy levels decreased >20%, even in the presence of folic acid fortification (RR, 0.85; 95% CI, 0.73 to 0.99; P = 0.04). In the corresponding comparison groups, the estimated RRs were attenuated and insignificant. Conclusions: Folic acid therapy can reduce CVD risk in patients with ESRD/ACKD by 15%. A greater beneficial effect was observed among those trials with no or partial folic acid fortification or a decrease in Hcy level >20% regardless of folic acid fortification.

AB - Background and objectives: The efficacy of folic acid therapy to lower homocysteine (Hcy) levels in an effort to reduce cardiovascular disease (CVD) risk in patients with ESRD or advanced chronic kidney disease (ACKD; creatinine clearance, 24 months (RR, 0.84; 95% CI, 0.72 to 0.98; P = 0.02), a decrease in Hcy level >20% (RR, 0.83; 95% CI, 0.73 to 0.95; P = 0.007), and no or partial folic acid fortification (RR, 0.80; 95% CI, 0.65 to 0.99; P = 0.04). The beneficial effect also was seen when Hcy levels decreased >20%, even in the presence of folic acid fortification (RR, 0.85; 95% CI, 0.73 to 0.99; P = 0.04). In the corresponding comparison groups, the estimated RRs were attenuated and insignificant. Conclusions: Folic acid therapy can reduce CVD risk in patients with ESRD/ACKD by 15%. A greater beneficial effect was observed among those trials with no or partial folic acid fortification or a decrease in Hcy level >20% regardless of folic acid fortification.

UR - http://www.scopus.com/inward/record.url?scp=79953020963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953020963&partnerID=8YFLogxK

U2 - 10.2215/CJN.05310610

DO - 10.2215/CJN.05310610

M3 - Article

C2 - 21088292

AN - SCOPUS:79953020963

VL - 6

SP - 482

EP - 488

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 3

ER -